By Colin Kellaher
The top executive of Medtronic's cardiovascular portfolio, Sean Salmon, is leaving the medical-technology company.
Medtronic on Wednesday said Skip Kiil, previously senior vice president and president of its cranial and spinal-technologies business, has replaced Salmon as executive vice president and president of the cardiovascular portfolio, which accounted for roughly 37% of the company's $33.5 billion in revenue for its latest fiscal year.
Medtronic said Salmon, who joined the company in 2004 and has been at the helm of the cardiovascular portfolio since the start of 2021, is entitled to severance payments and benefits and will remain an employee until Sept. 2.
The company said Michael Carter, vice president and general manager of its spine business, succeeds Kiil as senior vice president and president of the cranial and spinal-technologies business.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 21, 2025 07:23 ET (11:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。